… -cell lung carcinoma cell line A549 as a model to examine the therapeutic effects of luteolin.
… Untreated cells were primarily Annexin V-FITC and PI negative, indicating that they were …

… Lung cancer is the leading cause of cancer-related death in … lung tumor biology and
oncogenesis have provided several molecular targets for the treatment of non–small cell lung cancer …

… cell lung cancer (NSCLC) patients with EGFR activating mutations. However, therapeutic
effect is … We established a gefitinib-resistant cell model (PC9GR) by continually exposing PC9 …

… lung cancers with isotope-labeled glucose or glutamine and compared the fate of these
nutrients in tumor … To examine metabolic differences between lung tumor and normal tissue, we …

… lower in NSCLC tissues than in adjacent normal lung tissues (LAC). Furthermore, the
results from the Spearman correlation test showed a negative relationship between hsa-miR-125a-…

… Three possibilities are conceivable: Either this could represent a bystander phenomenon,
a side effect of a pathway functional to a different purpose. Secondly the upregulation of TLR9 …

… However the use of conventional drugs is limited due to the side effects and the resistant
phenotype acquired by tumours (58,59). Active compounds derived from plants, microbes and …

… Alternatively, uPAR-negative cancer cells may acquire uPAR expression under certain
culture conditions. Several uPAR-positive colonies have been picked and grown further for 2 …

… , thoracic surgery, and general lung cancer treatment to discuss the potential risks and …
is present in thyroid cancer tumors, whereas it is negative in lung cancer tumors. Pulmonary …

… Nevertheless, the administration of this drug at optimum doses and for a prolonged time has
been hampered by the prevalence of serious side effects, such as neutropenia, neuropathy, …